2022
Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue
Wisnewski AV, Cantley L, Luna J, Liu J, Smith RF, Hager K, Redlich CA. Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal Of Occupational And Environmental Medicine 2022, 64: 788-796. PMID: 36054278, PMCID: PMC9426317, DOI: 10.1097/jom.0000000000002617.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesHumansImmunoglobulin GIncidenceNorth AmericaVaccinationVideo GamesConceptsOccupational risk factorsCOVID-19 historyRisk factorsAnti-spike IgG levelsIndividual humoral responsesSerum antiviral antibodiesCOVID-19 vaccinationEnzyme-linked immunosorbent assayCOVID-19 ratesCOVID-19 incidenceSpike IgGVaccine nonrespondersVaccination statusIgG levelsVaccine responsesVaccine typesAntiviral antibodiesHumoral responseCOVID-19 casesVaccine availabilityImmunosorbent assayVaccinationInfectionMonthsParticipantsDevelopment and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses
Wisnewski AV, Liu J, Lucas C, Klein J, Iwasaki A, Cantley L, Fazen L, Luna J, Slade M, Redlich CA. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses. PLOS ONE 2022, 17: e0262657. PMID: 35041700, PMCID: PMC8765639, DOI: 10.1371/journal.pone.0262657.Peer-Reviewed Original ResearchConceptsPlaque reduction neutralization testCOVID-19 patientsVaccine responsesRecovered COVID-19 patientsSARS-CoV-2 immunityBooster vaccine dosesMRNA vaccine responsePost-vaccine seraCompetitive ELISAEnzyme 2 (ACE2) receptorReduction neutralization testType of vaccineSARS-CoV-2 spike protein receptorSpike protein receptorVaccine seraVaccine recipientsPost vaccinationVaccinated individualsVaccine dosesViral culturePrior historyViral neutralizationNeutralization testBooster shotsPost vaccine
2021
Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
Wisnewski AV, Redlich CA, Liu J, Kamath K, Abad QA, Smith RF, Fazen L, Santiago R, Luna J, Martinez B, Baum-Jones E, Waitz R, Haynes WA, Shon JC. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0252849. PMID: 34499652, PMCID: PMC8428655, DOI: 10.1371/journal.pone.0252849.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccine recipientsLinear epitopesSARS-CoV-2 neutralizationCOVID-19 mRNA vaccinesVaccine-induced IgGMRNA vaccine recipientsSARS-CoV-2 spike proteinDominant linear epitopeElicit IgGVaccine recipientsVaccine effectivenessMRNA vaccinesVaccination samplesImmune escapeHuman coronavirusesHealthy adultsSARS-CoVVaccine epitopesCritical epitopesAdverse responsesReverse vaccinologySpike proteinNatural infectionS2 subunitIgGHuman IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski AV, Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0249499. PMID: 34133415, PMCID: PMC8208542, DOI: 10.1371/journal.pone.0249499.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesAntigen-specific IgGMRNA vaccinesIgG levelsCOVID-19 mRNA vaccinationAntigen-specific IgG levelsInitial vaccine doseAntigen-specific IgASARS-CoV-2More rapid declineSecond vaccineVaccine doseMRNA vaccinationIgA responsesSerum levelsVaccine dosesSpecific IgGNatural immunityViral neutralizationIgAVaccinePeak levelsIgGVaccinationHuman IgGDelayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onset